구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 2개 · 임상 갱신 필요 1개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | enfortumab vedotin (Padcev, ASG-22ME, enfortumab-vedotin-ejfv) Astellas / Pfizer (Seagen)·Nectin-4 201 trials·t½ ADC ~3.4 days; free MMAE ~2.4 days | |
|---|---|---|
Overview Program | Padcev (enfortumab vedotin) | Tisotumab Vedotin |
Overview Company | Astellas / Pfizer (Seagen) | Genmab / Pfizer |
Overview Modality | ADC | ADC |
Overview Target | Nectin-4 | Solid Malignancies |
Overview Indication | Locally advanced or metastatic urothelial carcinoma | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Overview Phase | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved |
Positioning Key differentiator | Nectin-4 is near-uniformly expressed in urothelial carcinoma, giving an unusually clean tumor-selective target in that tissue. | — |
Positioning Known limitation | Nectin-4 loss, MMAE efflux, and tubulin alterations. | — |
Positioning Development positioning | 1L standard of care in urothelial carcinoma with pembrolizumab. | — |
Technology Payload | MMAE (monomethyl auristatin E, tubulin inhibitor) | — |
Technology Linker | Protease-cleavable mc-vc-PAB, DAR ~3.8 | — |
Technology DAR | DAR 3.8 | — |
MoA Mechanism | Binds Nectin-4 on urothelial tumor cells, internalizes, and releases MMAE after cathepsin B cleavage; microtubule disruption arrests mitosis and triggers apoptosis. | — |
MoA Biomarker | Nectin-4 expression is high in urothelial carcinoma; no companion diagnostic required. | — |
PK/PD Half-life | ADC ~3.4 days; free MMAE ~2.4 days | — |
PK/PD Species | Cynomolgus monkey, ORR, PFS, OS | — |
PK/PD Animal (cat.) | Human, NHP, In vitro | — |
PK/PD Experiment | Pharmacokinetic | — |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | — |
Toxicology Major finding | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Pneumonitis: Severe, life-threatening, or fatal pneumonitis may occur |
Toxicology CRS | N/A | — |
Clinical Safety signal | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Pneumonitis: Severe, life-threatening, or fatal pneumonitis may occur |
Clinical Selected reported efficacy | ORR 67.7% | ORR 23.8% |
Clinical Reported ORR | 67.7% (EV + pembrolizumab) | 23.8% |
Clinical Reported PFS | 12.5 mo vs 6.3 mo (chemo) | — |
Clinical Reported OS | 31.5 mo vs 16.1 mo (chemo) | — |
Clinical Result source | EV-302 / KEYNOTE-A39 (NCT04223856) | ClinicalTrials.gov NCT03438396 |
Clinical Program phase | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT04223856 | NCT03438396 |
Preclinical Animal (cat.) | Human, Mouse, In vitro | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 2개 · 임상 갱신 필요 1개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | enfortumab vedotin (Padcev, ASG-22ME, enfortumab-vedotin-ejfv) Astellas / Pfizer (Seagen)·Nectin-4 201 trials·t½ ADC ~3.4 days; free MMAE ~2.4 days | |
|---|---|---|
Overview Program | Padcev (enfortumab vedotin) | Tisotumab Vedotin |
Overview Company | Astellas / Pfizer (Seagen) | Genmab / Pfizer |
Overview Modality | ADC | ADC |
Overview Target | Nectin-4 | Solid Malignancies |
Overview Indication | Locally advanced or metastatic urothelial carcinoma | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Overview Phase | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved |
Positioning Key differentiator | Nectin-4 is near-uniformly expressed in urothelial carcinoma, giving an unusually clean tumor-selective target in that tissue. | — |
Positioning Known limitation | Nectin-4 loss, MMAE efflux, and tubulin alterations. | — |
Positioning Development positioning | 1L standard of care in urothelial carcinoma with pembrolizumab. | — |
Technology Payload | MMAE (monomethyl auristatin E, tubulin inhibitor) | — |
Technology Linker | Protease-cleavable mc-vc-PAB, DAR ~3.8 | — |
Technology DAR | DAR 3.8 | — |
MoA Mechanism | Binds Nectin-4 on urothelial tumor cells, internalizes, and releases MMAE after cathepsin B cleavage; microtubule disruption arrests mitosis and triggers apoptosis. | — |
MoA Biomarker | Nectin-4 expression is high in urothelial carcinoma; no companion diagnostic required. | — |
PK/PD Half-life | ADC ~3.4 days; free MMAE ~2.4 days | — |
PK/PD Species | Cynomolgus monkey, ORR, PFS, OS | — |
PK/PD Animal (cat.) | Human, NHP, In vitro | — |
PK/PD Experiment | Pharmacokinetic | — |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | — |
Toxicology Major finding | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Pneumonitis: Severe, life-threatening, or fatal pneumonitis may occur |
Toxicology CRS | N/A | — |
Clinical Safety signal | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Pneumonitis: Severe, life-threatening, or fatal pneumonitis may occur |
Clinical Selected reported efficacy | ORR 67.7% | ORR 23.8% |
Clinical Reported ORR | 67.7% (EV + pembrolizumab) | 23.8% |
Clinical Reported PFS | 12.5 mo vs 6.3 mo (chemo) | — |
Clinical Reported OS | 31.5 mo vs 16.1 mo (chemo) | — |
Clinical Result source | EV-302 / KEYNOTE-A39 (NCT04223856) | ClinicalTrials.gov NCT03438396 |
Clinical Program phase | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT04223856 | NCT03438396 |
Preclinical Animal (cat.) | Human, Mouse, In vitro | — |
추천 비교
추천 비교